Q-omics provides the consensus-scored CD160 profile across patient tissues and cancer cell-line models. CD160 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CD160 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CD160 RNA expression shows 19,999 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, COAD, and UVM as cancer lineages where CD160 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD160 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD160 survival associations across molecular data types. CD160 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD160 RNA expression–survival associations across cancer types. High CD160 expression shows unfavorable associations in LGG, UVM and ACC, but favorable associations in SKCM, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CD160 RNA expression.
This table summarizes CD160 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD160. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD160 shows lower tumor expression in COAD, LUSC, LUAD, LIHC and BLCA and higher tumor expression in KIRC. The COAD box plot shows higher CD160 RNA expression in normal versus tumor tissue (log2 FC = −1.055, t-test p < 0.001).
This table shows molecular features associated with CD160 in patient tissues and cancer cell lines. In patient samples, CD160 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD160 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LIVER.
